findmyKOL

Elias Sotirchos, MD

Basic profile

Johns Hopkins University

ORCID↗NPI↗
✓ Full record
RegionBaltimore, MD · NortheastSpecialtyNeurologyFocusNeurology
Active KOLfindmyKOL type: NationalLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH funding2020–2026Why? →

Elias Sotirchos is a Neurology physician affiliated with Johns Hopkins University. OpenAlex indexes 153 publications with 4,891 citations (h-index 36).

Overview

Scholarship

indexed output and impact (OpenAlex)
153publications

Distinct works indexed by OpenAlex, matched via ORCID.

4,891citations

Total citations across indexed works.

36h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
11companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
2NIH grants · 2020–2026

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

1800 Orleans St
Sheikh Zayed Tower, Room 6005
Baltimore, MD 212870010

Telephone

410-955-6626

Provider last certified this registry record 15 May 2020.

View the NPPES registry record

Industry payments

11 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Nervous system

    49.4%
    Gabapentinoids26.6%
    Gabapentin100%
    Part D≥12 patients
    Opioid Agonist14.6%
    Tramadol Hcl100%
    Part D<11 patients

    + 1 more class in this area

  • Cancer & immunology

    36.7%
    Complement Inhibitor21.5%
    Ultomiris65%Soliris35%
    Part D<11 patients
    Interleukin inhibitors15.2%
    Enspryng100%
    Part D<11 patients
  • Musculoskeletal

    13.9%
    gamma-Aminobutyric Acid-ergic Agonist13.9%
    Baclofen100%
    Part D<11 patients
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

2 NIH research awards on record, funded 2020–2026 per NIH RePORTER. The latest:

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”